Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in nEGFR+ TNBC
NCT02720185Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2017
- Primary completion
- Jul 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in triple-negative breast cancer (TNBC), sponsored by University of Wisconsin–Madison. Started May 2017; status: terminated.
02
Drugs
dasatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02720185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720185.